Patents Assigned to Western University Health Sciences
-
Publication number: 20170065614Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: September 19, 2016Publication date: March 9, 2017Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJJI
-
Patent number: 9566238Abstract: This invention is directed to a novel method of treating an individual suffering from a bacterial infection, such as bacterial infections of various tissues or organs of an individual. In general, the method of treatment involves administering to an individual a pharmaceutical formulation that comprises a liposome-encapsulated antimicrobial agent, wherein polyethylene glycol (PEG) molecules are covalently attached to the surface of the liposomes.Type: GrantFiled: June 20, 2011Date of Patent: February 14, 2017Assignee: WESTERN UNIVERSITY OF HEALTH SCIENCESInventors: Andrew Pumerantz, Guru Betageri, Jeffrey Jinghua Wang
-
Publication number: 20160375036Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: August 29, 2016Publication date: December 29, 2016Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJJI
-
Patent number: 9492387Abstract: The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly-water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substance's dissolution.Type: GrantFiled: October 31, 2011Date of Patent: November 15, 2016Assignee: WESTERN UNIVERSITY OF HEALTH SCIENCESInventors: Guru V. Betageri, Sunil A. Agnihotri, Kumaresh Soppimath
-
Patent number: 9445995Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: January 26, 2015Date of Patent: September 20, 2016Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLCInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Patent number: 9182399Abstract: Specific applications of particles and particle agglomerates with semiconductor surfaces are provided. The particles and particle agglomerates display a high affinity for viral particles, and may be used therapeutically and/or prophylactically to treat or prevent viral infections. The particles and particle agglomerates may also be used to remove viral particles from a surface or fluid, e.g., as an absorbent in a filter, applied to surfaces to render them virostatic, and as tool to handle viral particles, e.g., for research, diagnostic, or decontamination purposes.Type: GrantFiled: August 24, 2012Date of Patent: November 10, 2015Assignees: Christian-Albrechts-Universitaet Zu Kiel, Universitatsklinikum Schleswig-Holsten, Western University of Health Sciences, The Board of Trustees of the University of IllinoisInventors: Rainer Adelung, Yogendra Kumar Mishra, Claudia Röhl, Deepak Shukla, Frank Spors, Vaibhav Tiwari
-
Publication number: 20150157571Abstract: The invention provides pharmaceutical compositions containing a vehicle for the targeted delivery of therapeutic and diagnostic agents for the treatment of hyperproliferative diseases. The targeting component of the vehicle is a cystine molecule that is coupled to the cargo component, which can be either a therapeutic or diagnostic agent or to a nanoparticle composition that contains the therapeutic agent or diagnostic. The invention also provides methods of treating hyperproliferative disorders by targeting hyperproliferative disease cells for the targeted delivery of a therapeutic or diagnostic agent.Type: ApplicationFiled: September 10, 2012Publication date: June 11, 2015Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventors: Maria Polikandritou Lambros, Ying Huang
-
Patent number: 8957053Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: January 7, 2014Date of Patent: February 17, 2015Assignees: Tesorx Pharma, LLC, Western University Health SciencesInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Patent number: 8889180Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.Type: GrantFiled: October 7, 2011Date of Patent: November 18, 2014Assignee: Western University of Health SciencesInventor: Guru V. Betageri
-
Publication number: 20140112986Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: ApplicationFiled: January 7, 2014Publication date: April 24, 2014Applicants: TESORX PHARMA, LLC, WESTERN UNIVERSITY OF HEALTH SCIENCESInventors: Guru V. BETAGERI, Ramachandran THIRUCOTE, Veeran Gowda KADAJJI
-
Publication number: 20140056947Abstract: Specific applications of particles and particle agglomerates with semiconductor surfaces are provided. The particles and particle agglomerates display a high affinity for viral particles, and may be used therapeutically and/or prophylactically to treat or prevent viral infections. The particles and particle agglomerates may also be used to remove viral particles from a surface or fluid, e.g., as an absorbent in a filter, applied to surfaces to render them virostatic, and as tool to handle viral particles, e.g., for research, diagnostic, or decontamination purposes.Type: ApplicationFiled: August 24, 2012Publication date: February 27, 2014Applicants: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, WESTERN UNIVERSITY OF HEALTH SCIENCES, UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEINInventors: Rainer Adelung, Yogendra Kumar Mishra, Claudia Röhl, Deepak Shukla, Frank Spors, Vaibhav Tiwari
-
Patent number: 8658202Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.Type: GrantFiled: November 30, 2004Date of Patent: February 25, 2014Assignee: Western University of Health SciencesInventor: Guru V. Betageri
-
Publication number: 20130310397Abstract: The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly- water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substance's dissolution.Type: ApplicationFiled: October 31, 2011Publication date: November 21, 2013Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventors: Guru V. Betageri, Sunil A. Agnihotri, Kumaresh Soppimath
-
Publication number: 20130218546Abstract: This invention relates to a novel, bacterial GTP Cyclohydrolase Type IB enzyme, and the crystal structure thereof.Type: ApplicationFiled: December 7, 2012Publication date: August 22, 2013Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventor: WESTERN UNIVERSITY OF HEALTH SCIENCES
-
Publication number: 20130177528Abstract: Provided herein are compositions and methods for inhibiting viral infection of a host cell. The methods comprise contacting the the host cell with an effective amount of one or more polypeptides having a disintegrin domain. The polypeptide can be CN, VCN or modified ADAM-derived polypeptide (MAP), or a fusion protein comprising a CN, VCN or MAP.Type: ApplicationFiled: November 12, 2012Publication date: July 11, 2013Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, UNIVERSITY OF SOUTHERN CALIFORNIAInventors: University of Southern California, Western University of Health Sciences
-
Patent number: 8328934Abstract: This invention relates to a novel, bacterial GTP Cyclohydrolase Type IB enzyme, and the crystal structure thereof.Type: GrantFiled: April 8, 2010Date of Patent: December 11, 2012Assignee: Western University of Health SciencesInventors: Manal A. Swairjo, Dirk Iwata-Reuyl, Valerie de Crecy-Lagard
-
Publication number: 20120027864Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventor: Guru V. BETAGERI
-
Publication number: 20110093959Abstract: The present invention provides for anrelate to an animal model for characterizing emesis, and for screening and characterizing emetic and antiemetic agents. In several embodiments, the Least Shrew, Cryptotis parva, provides a specific and rapid behavioral animal model to screen concomitantly both the CNS penetration and the antiemetic potential of antiemetic agents to relieve, for example, chemotherapy-induced emesis.Type: ApplicationFiled: January 30, 2009Publication date: April 21, 2011Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventor: Nissar A. Darmani
-
Publication number: 20100291608Abstract: This invention relates to a novel, bacterial GTP Cyclohydrolase Type IB enzyme, and the crystal structure thereof.Type: ApplicationFiled: April 8, 2010Publication date: November 18, 2010Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventors: Manal A. SWAIRJO, Dirk IWATA-REUYL, Valerie de CRECY-LAGARD
-
Patent number: 6849269Abstract: This invention relates to proliposomal drug-delivery systems for medicaments. In particular, it relates to enteric-coated proliposomal formulations for poorly water soluble drugs and methods for making the same. The drug delivery system comprises a pharmaceutical agent, a phospholipid and a coating material. The present invention provides enhanced stability and bioavailability for pharmaceutical formulations.Type: GrantFiled: April 24, 2002Date of Patent: February 1, 2005Assignee: Western University of Health SciencesInventor: Guru V. Betageri